BioCentury | Oct 14, 2020
Product Development

A third leading COVID program enters holding pattern as NIH pauses testing of Lilly’s mAb

...mAbs Skyrizi from AbbVie and Boehringer and lenzilumab...
...IV doses, each eight hours apart, of lenzilumab...
...Wong bamlanivimab, LY-CoV555 (LY3819253) Skyrizi, risankizumab (ABBV-066, BI 655066) lenzilumab (KB003) Moderna...
BioCentury | Sep 2, 2020
Product Development

COVID-19 Quick Takes: NAS framework on vaccine allocation prioritizes higher risk groups

...data from a case control study suggesting lenzilumab...
...an emergency IND with 27 matched controls. Lenzilumab, which...
...Compound #), REGN88 (Compound #), sarilumab (Generic) lenzilumab (KB003) AstraZeneca...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...COO and CFO. He was CFO of Iovance Biotherapeutics Inc. (NASDAQ:IOVA). The company’s anti-GM-CSF mAb lenzilumab...
BioCentury | Jul 30, 2020
Product Development

Finding immunosuppression sweet spot could be next up for COVID-19 after second IL-6 failure

...Center . This week, NIH’s National Institute of Allergy and Infectious Diseases selected anti-GM-CSF mAb lenzilumab...
...interim efficacy analysis expected after each cohort enrolls 50 patients. Humanigen said published data demonstrating lenzilumab’s...
...Brand), RG1569 (Compound #), R1569 (Compound #), tocilizumab (Generic), RoActemra (Informal), MRA (Informal), Actemra (Informal) lenzilumab (KB003) Humanigen...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

...Preclinical 2058 Mayo Clinic / Humanigen Inc. (Pink:HGEN) CD19 Granulocyte macrophage colony-stimulating factor (GM-CSF; CSF2) (lenzilumab...
BioCentury | Aug 8, 2016
Clinical News

Lenzilumab: Phase I started

...began an open-label, U.S. Phase I trial to evaluate 200, 400 and 600 mg IV lenzilumab...
...up to 18 patients. KaloBios Pharmaceuticals Inc. (Pink:KBIOQ), South San Francisco, Calif. Product: Lenzilumab ( KB003...
BioCentury | Jan 4, 2016
Finance

Big band swing

...said it would suspend the activation of a Phase I trial of leukemia compound lenzilumab (KB003...
...FBI on securities fraud charges, he was terminated as CEO and resigned from KaloBios' board. Lenzilumab...
BioCentury | Jan 4, 2016
Company News

KaloBios cancer news

...the University of California Davis postponed the start of a Phase I trial of KaloBios' lenzilumab...
BioCentury | Dec 22, 2015
Clinical News

UC Davis delays KaloBios trial on Shkreli news

...University of California Davis postponed the start of a Phase I trial of lenzilumab ( KB003...
...begin the 31-patient study of lenzilumab this year. The company did not respond to inquiries. Lenzilumab...
BioCentury | Nov 21, 2015
Company News

KaloBios names Shkreli CEO, revives leukemia program

...shareholder approval. By YE15, KaloBios intends to begin a 31-patient Phase I/II study of lenzilumab (KB003...
...13, KaloBios said it would wind down operations and discontinue development of its programs, including lenzilumab...
Items per page:
1 - 10 of 34